pancreatic ductal adenocarcinoma

[Translational Oncology] Investigators generated a prospective cohort of 27 consecutive biopsied derived pancreatic organoids and included them in the signature identification strategy.

[Cancer Cell International] Investigators characterized the function of eukaryotic translation initiation factors (eIFs) in epithelial-mesenchymal-transition (EMT) and metastasis in pancreatic cancer cells to investigate whether eIFs and downstream c-MYC affect EMT and metastasis by joint interference.

[Cancer Research] Using genetically defined models, researchers showed that HDAC2 was a cellular fitness factor that controls cell cycle in vitro and metastasis in vivo, particularly in undifferentiated, mesenchymal pancreatic ductal adenocarcinoma cells.

[Science Translational Medicine] Scientists identified and characterized resistance mechanisms to a FIRINOX chemotherapy regimen because it is the most aggressive regimen currently used clinically for patients with pancreatic ductal adenocarcinoma.

[Cell] In vivo, scientists identified a new intermediate pancreatic ductal adenocarcinoma transcriptional cell state and uncovered distinct site- and state-specific tumor microenvironments.

[Journal of Physiology and Biochemistry] Scientists identified that a 3D co-culture model of MIA PaCa-2 or PANC-1 with cancer-associated fibroblasts showed an increased chemoresistance to gemcitabine when compared to standard 2D mono-cultures a difference to paclitaxel which showed no measurable difference between the 2D and 3D models, suggesting a complex interaction between the drug in study and the cell type used.